封面
市場調查報告書
商品編碼
1138411

病毒載體和質粒 DNA 製造的全球市場 - 2022-2029

Global Viral Vector and Plasmid DNA Manufacturing Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

全球病毒載體和質粒 DNA 製造市場的增長受到多種因素的推動,例如 DNA 疫苗開發、基因治療、免疫治療等對病毒載體和質粒 DNA 製造的需求增加。

預計在預測期內,對基因治療和免疫治療的需求不斷增長將推動全球病毒載體和質粒 DNA 製造市場。

該市場的驅動力是對用於開發 DNA 疫苗、基因療法、免疫療法等的病毒載體和質粒 DNA 生產的需求不斷增加。病毒載體和質粒DNA因其轉染效率高、基因轉移效率高、基因表達穩定等優點而不斷發展壯大。驗證病毒載體和質粒 DNA 有效性和安全性的臨床試驗正在增加。

病毒載體和質粒 DNA 的合同製造企業數量正在增加。例如,2019 年 12 月,Helicsmith Co., Ltd. 和 Genopis Inc. 開始了質粒 DNA 製造的合同製造業務。我們將通過可行性運行安裝額外的小型反應器(60-300L、6-30L)並開始小批量生產服務。 Genopis 擁有正確的技術和質量體系。

多家公司已與多家組織合作生產病毒載體和質粒 DNA。例如,2020 年 6 月,Oxford Biomedica plc 與為提供英國首個戰略性疫苗開發和先進製造能力而成立的非營利組織疫苗製造與創新中心 (VMIC) 簽署了合作協議。這項為期五年的協議將使兩家公司能夠生產基於病毒載體的疫苗,並有助於英國國內在疫苗製造這一專業領域的產能快速增長。根據協議條款,VMIC 將向 Oxford Biomedica 提供製造設備,並在 Oxford Biomedica 位於英國牛津的新 7,800 平方米商業生產設施 Oxbox 內建立兩個新的 GMP 製造室。

與載體和質粒治療相關的誘變風險可能會阻礙市場增長

基因工程病毒載體和質粒 DNA 用於多種基因和免疫療法。這些轉基因載體和質粒存在插入誘變風險,可能會抑制市場增長,基因治療的高成本也可能限制市場增長。

行業分析

全球病毒載體和質粒 DNA 製造市場根據波特五力、監管分析、供應鏈分析和價格分析等各種行業因素對市場進行了深入分析。

全球病毒載體和質粒 DNA 製造市場報告提供了大約 45 多個市場數據表、40 多個圖表和 180 頁的組成。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 對基因療法和免疫療法的需求不斷增長
      • 癌症和遺傳疾病等疾病的發病率增加
    • 限制因素
      • 致突變風險
      • 基因治療費用高
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結
  • 其他

第 7 章按產品類型

  • 質粒 DNA
  • 病毒載體
    • 逆轉錄病毒載體
    • 腺病毒載體
    • 慢病毒載體
    • 腺相關病毒載體
    • 其他
  • 非病毒載體

第 8 章. 按應用程序

  • 癌症
  • 遺傳性疾病
  • 感染
  • 其他疾病

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按產品類型進行基準測試
  • 值得關注的重點公司列表

第 11 章公司簡介

  • Brammer Bio(Thermo Fisher Scientific Inc.)
    • 公司簡介
    • 按產品類型劃分的產品組合和內容
    • 主要亮點
    • 財務摘要
  • Cobra Biologics
  • Cell and Gene Therapy Catapult
  • FinVector Vision Therapies
  • Fujifilm Diosynth Biotechnologies
  • MassBiologics
  • SIRION Biotech
  • Merck KGaA Inc.
  • Thermo Fisher Scientific
  • Uniqure NV

第12章 全球病毒載體和質粒 DNA 製造市場-DataM

簡介目錄
Product Code: DMBT2571

Market Overview

Viral Vector and Plasmid DNA Manufacturing Market size was valued US$ 2.85 billion in 2021 and is estimated to reach US$ XX billion by 2029, growing at a CAGR of 14.2% during the forecast period (2022-2029).

The viral vector is referred to as the tool for delivering genetic material into cells. The modified viral vector is used as a viral vector in gene therapy. Plasmid DNA is a bacterial smaller, circular, and extrachromosomal DNA used in different molecular genetic research such as gene therapy, gene transfer, and recombinant DNA technology due to its self-replication property. A gene of interest is transferred into the target cell for studying the function or expression of a gene.

Market Dynamics

The global viral vector and plasmid DNA manufacturing market growth is driven by several factors such as increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others.

Increasing demand for gene therapy and immunotherapy is expected to drive the global viral vector and plasmid DNA manufacturing market during the forecast period.

The market is driven by the increasing demand for viral vectors and plasmid DNA manufacturing for developing DNA vaccines, gene therapy, immunotherapy, and others. There are growing viral vectors & plasmid DNA due to their advantages such as high transfection efficiency, effective gene delivery, and stable gene expression. There is an increase in the number of clinical studies examining the viral vectors' efficacy and safety and plasmid DNA.

There is an increase in the contract manufacturing business launch for viral vectors and plasmid DNA manufacturing. For instance, in December 2019, Helixmith Co., Ltd. and Genopis launched the contract manufacturing business for plasmid DNA production. The company would establish additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-volume production service. Genopis is equipped with the right technologies and quality systems.

Several companies are entering into a collaboration with several organizations to manufacture viral vectors and plasmid DNA. For instance, in June 2020, Oxford Biomedica plc entered into a collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization established to provide the UK's first strategic vaccine development and advanced manufacturing capability. This five-year agreement would involve the organizations working collaboratively to enable the manufacture of viral vector-based vaccines, contributing to a rapid increase in the United Kingdom domestic capacity for this specialized vaccine manufacturing field. Under the terms of the agreement, VMIC would provide manufacturing equipment for Oxford Biomedica to equip two new GMP manufacturing suites within Oxford Biomedica's new 7,800 m2 commercial manufacturing center, Oxbox, located in Oxford, United Kingdom.

Risk of mutagenesis associated with vector or plasmid treatments are likely to hinder the market growth

As genetic engineered viral vector and plasmid DNA are being used in various gene therapy and immunotherapy procedures. There is a risk of insertional mutagenesis associated with these genetic modified vectors and plasmids that can restrain the market growth and the high cost of gene treatments can also limit the growth of market.

Industry Analysis

The global viral vector and plasmid DNA manufacturing market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis.

Segment Analysis

The viral vector segment is expected to hold the largest market share in global viral vector and plasmid DNA manufacturing market

The global viral vector and plasmid DNA manufacturing market is segmented on the product type the plasmid DNA, viral vector, and non-viral vector. The viral vector segment accounts for the highest market growth due to the increasing penetration of the viral vectors for targeted delivery, efficient transduction, and controlled gene expression. There is an increase in the viral vectors' usage due to their efficiency in delivering genes into the target cells and protecting the new genes from degradation. Different types of viral vectors such as retrovirus, lentivirus, adenovirus, adeno-associated virus, and herpes simplex virus are used for transferring the nucleic acids into the genetic makeup of cells. Out of these viral vectors, adenovirus and retrovirus are widely used worldwide as these viral vectors have the integration ability with large transgenes and easy production at high titers.

Several companies are focusing on expanding the manufacturing facilities for the viral vectors to meet the increasing demand. For instance, in May 2019, Thermo Fisher Scientific Inc. had opened its new $90 million viral vector contract development and manufacturing organization (CDMO) site in Lexington, MA. The 50,000-square-foot facility would support the development, testing, and manufacture of viral vectors essential for advancing gene and cell therapies globally.

Further, the market is also classified based on cancer, genetic disorder, infectious disease, and other diseases. The cancer segment accounts for the highest market share due to the higher usage of the viral vector and plasmid DNA for delivering the anti-cancer genes. Several biotechnology and pharmaceutical companies are examining the viral vectors or plasmid DNA encoding a therapeutic gene, often an immunomodulatory or suicide gene, in the various cancer gene therapy trials. Clinical studies have demonstrated that the injection of plasmid DNA encoding a cytokine gene has a significant antitumor effect. There are increasing research and development activities for gene therapies and other advanced cell therapies to treat various cancers. The increase in the approval of the viral vector and plasmid DNA-based therapies shall stimulate market growth. For instance, the lentiviral vector-based CAR-T cell therapies are approved for treating Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma.

Geographical Analysis

North America region holds the largest market share in the global viral vector and plasmid DNA manufacturing market

By region, the global viral vector and plasmid DNA manufacturing market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global viral vector and plasmid DNA manufacturing market and is expected to grow at the highest CAGR during the forecasted period due to the increasing number of clinical studies for evaluating the use of the viral vector and plasmid DNA for the treatment of the genetic disorders, cancer, and infectious diseases. The increase in the approval of advanced cell therapies shall stimulate market growth. There is growing research and development activities of gene therapies. Several companies, institutes, associations, and foundations raise the investment and funding to develop gene therapies. The growing initiatives by the Food and Drug Administration (FDA) for improving the regulatory support for cell and gene therapy shall boost the demand for viral vector and plasmid DNA manufacturing.

The Asia Pacific is expected to witness positive market growth due to the growing clinical transformation and industrialization of advanced therapies medicinal products, including gene therapy manufacturing. There is a presence of several companies manufacturing the viral vector and plasmid DNA. Contract manufacturers are providing several services for viral vector and plasmid DNA manufacturing. There is growing adoption of advanced technologies for manufacturing viral vectors and plasmid DNA.

Competitive Landscape

The global viral vector and plasmid DNA manufacturing market is highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.

The major players enter into collaborations, acquisitions, mergers, and licensing activities to increase their market presence. For instance, in Apr 2022, FUJIFILM Diosynth Biotechnology, a Contract Development Manufacturing Organisation that develops recombinant biopharmaceuticals and viral gene therapy announced its manufacturing agreement with Chimeron Bio, RNA company that develops self-amplifying RNA vaccines and therapies that are developed by their own proprietary ChaESAR RNA delivery platform.

In March 2019, Merck entered into the non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on plasmid and viral vector manufacturing. The manufacturing of high-quality plasmids and viral vectors would help in the commercialization of cell and gene therapy. This collaboration would help the company accelerate the industrialization and commercialization of cell and gene therapy in China. Merck would provide GenScript with comprehensive products, training, and consulting services covering process design, facility concept design, and quality management system set-up from lab development to large-scale GMP manufacturing.

Key Companies to Watch

Brammer Bio:

Overview: Brammer Bio is a contract development and manufacturing organization (CDMO) that develops and manufactures viral vector and helps biopharmaceutical companies to deliver breakthrough medicines in form of gene modified cell therapies to patients. Founded in 2013 and headquartered in Florida.

Product Portfolio:

Lipofectamine CRISPRMAX Cas9 Transfection Reagent: It is a 1st lipid nanoparticle optimized reagent for transfection use for CRISPR-Cas9 protein delivery. It is a cost effective, high throughput friendly alternate for electroporation.

Key Developments: In May 2019, Thermo Fisher Scientific Inc., company serving science announced acquisition of Brammer Bio, viral vector manufacturing company for gene therapies for around $1.7 billion.

The global viral vector and plasmid DNA manufacturing market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers:
      • 4.1.1.1. The growing demand of gene therapy and immunotherapy
      • 4.1.1.2. Increase in the incidence of diseases such as cancer and genetic disorders.
    • 4.1.2. Restraints:
      • 4.1.2.1. Risk of mutagenesis
      • 4.1.2.2. High cost of gene therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion
  • 6.7. Others

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment
    • 7.1.2. Market Attractiveness Index, By Product Type Segment
  • 7.2. Plasmid DNA
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Viral Vector
    • 7.3.1. Retroviral Vectors
    • 7.3.2. Adenoviral Vectors
    • 7.3.3. Lentiviral Vectors
    • 7.3.4. Adeno-Associated Viral Vectors
    • 7.3.5. Others
  • 7.4. Non-Viral Vector

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cancer
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Genetic Disorder
  • 8.4. Infectious Disease
  • 8.5. Other Diseases

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

10. Competitive Landscape

  • 10.1. Key Developments and Strategies
  • 10.2. Company Share Analysis
  • 10.3. Product Type Benchmarking
  • 10.4. List of Key Companies to Watch

11. Company Profiles

  • 11.1. Brammer Bio (Thermo Fisher Scientific Inc.)
    • 11.1.1. Company Overview
    • 11.1.2. Product Type Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Cobra Biologics
  • 11.3. Cell and Gene Therapy Catapult
  • 11.4. FinVector Vision Therapies
  • 11.5. Fujifilm Diosynth Biotechnologies
  • 11.6. MassBiologics
  • 11.7. SIRION Biotech
  • 11.8. Merck KGaA Inc.
  • 11.9. Thermo Fisher Scientific
  • 11.10. Uniqure NV

LIST NOT EXHAUSTIVE

12. Global Viral Vector and Plasmid DNA Manufacturing Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Usability
  • 12.3. Contact Us